Abbott Tumbles on Q4 Miss & Weak Outlook 01/22/26
/
RSS Feed
Abbott Tumbles on Q4 Miss & Weak Outlook 01/22/26
Key Stories:
- Abbott Laboratories, the medical devices and healthcare giant, saw its shares tumble today after reporting fourth-quarter earnings and sales that fell short of Wall Street’s expectations. The company projected full-year adjusted earnings in the range of $5.55 to $5.80 per share, a figure that disappointed analysts. A key factor weighing on performance was its nutrition business, which acted as a drag on overall results. Abbott also set a full-year organic sales growth target of 6.5% to 7.5%. Investors will be watching closely to see how the company navigates these challenges, particularly in its consumer-facing segments. Read more
- Turning to the banking sector, we’re seeing some interesting developments in consumer credit. Bank of America and Citigroup, two of the nation’s largest financial institutions, are reportedly considering options to introduce new credit cards featuring an interest rate cap of just 10%. This potential move is said to be in response to demands from President Donald Trump. While details are still emerging, such a cap could significantly alter the landscape of consumer lending for these major banks, potentially impacting their profitability in the highly competitive credit card market. It’s a story to monitor for its broader implications on financial services. Read more
- And finally, industrial conglomerate Honeywell International has been a topic of discussion for market watchers, including expert Jim Cramer, who has been highlighting the company’s strategic spinoffs. Honeywell, a diversified global giant known for aerospace, building technologies, and performance materials, has seen its shares rise by a modest 2.7% over the past year. However, it’s shown stronger momentum year-to-date, gaining 11%. JPMorgan analysts are reportedly among those tracking Honeywell’s moves closely, as the company continues to refine its portfolio through strategic divestitures, aiming to unlock greater shareholder value and focus on core growth areas. Read more
Keywords: ABT, BAC, C, HON, Jim Cramer, Q4 results, analyst commentary, banking sector, consumer lending, credit cards, earnings miss, financial services, guidance, industrial conglomerate, interest rate cap, medical devices, nutrition business, portfolio strategy, spinoffs, stock performance, stock slump